<div><br />
</div>
<div><strong>Do you believe miracles are impossible and out of reach?</strong>
</div>
<div>Together, we can make one happen for Anwar. ❤️
</div>
<div><strong>A life-changing gene therapy </strong>could<strong> </strong>give<strong> Anwar a </strong>chance to fight <strong>muscular</strong> <strong>dystrophy</strong> and change his life<strong>forever</strong>
</div>
<div><br />
</div>
<div><strong>the Enemy: A Journey with LGMD2D</strong>
</div>
<div><br />
</div>
<div><br />
</div>
<div>Imagine waking up one day to realize that time has become your greatest enemy—that you are racing against it while fighting a rare, progressive disease that stole your childhood and now threatens to steal your future.
</div>
<div><br />
</div>
<div>My life changed forever in June 2021, when I was diagnosed with Limb-Girdle Muscular Dystrophy type 2D (LGMD2D). Since that day, time has no longer felt like something that simply passes. It has become something I constantly race against.
</div>
<div><br />
</div>
<div><strong>LGMD2D</strong> is a rare genetic muscle disease that progressively weakens the muscles responsible for some of the most basic movements of daily life. Things that most people do without thinking—standing up, sitting down, climbing stairs, lifting an arm, walking across a room can become exhausting battles.
</div>
<div><br />
</div>
<div>When the Simplest Movements Become a Battle
</div>
<div>There is a strange kind of grief in having to think about movements that everyone else performs automatically.
</div>
<div><br />
</div>
<div>I have forgotten what it feels like to walk without fear.
</div>
<div><br />
</div>
<div>I have forgotten how people sit down without pain, without calculating the movement, without wondering whether their muscles will cooperate.
</div>
<div><br />
</div>
<div>I watch people walk, rise from chairs, climb stairs, or simply change position, and I realize how invisible these abilities are until you begin to lose them.
</div>
<div><br />
</div>
<div>For me, movement is no longer something I can take for granted. Every step can carry a question: <strong>How many more steps will I have tomorrow?</strong>
</div>
<div><br />
</div>
<div>The greatest fear I carry is not simply weakness. It is the possibility of losing my ability to walk one day because the treatment I need did not arrive in time.
</div>
<div><br />
</div>
<div>And in muscular dystrophy, there is a phrase that carries enormous weight:
</div>
<div><br />
</div>
<div>“<strong>Time is muscle.”</strong>
</div>
<div><br />
</div>
<div><strong>Why Is Time So Important?</strong>
</div>
<div><br />
</div>
<div>My disease is progressive. This means that the longer the disease advances without an effective treatment, the more muscle function may be lost.
</div>
<div><br />
</div>
<div>At the cellular level, repeated muscle injury and degeneration can eventually lead to the replacement of functional muscle tissue with fibrotic tissue and fat. Fibrosis means that connective tissue, particularly collagen, accumulates within muscle as part of an abnormal repair process. Over time, this reduces the amount of contractile muscle available to generate strength and can make restoring lost function increasingly difficult.
</div>
<div><br />
</div>
<div>That is why time matters so much.
</div>
<div><br />
</div>
<div>The goal is not simply to treat a number on a medical report. The goal is to preserve the muscles that allow me to stand, walk, breathe, move, and live independently.
</div>
<div><br />
</div>
<div>Every month matters because muscle that is still functioning is muscle worth protecting.
</div>
<div><br />
</div>
<div><strong>The Hope of Gene Therapy</strong>
</div>
<div><br />
</div>
<div>LGMD2D is caused by mutations affecting the SGCA gene, which encodes alpha-sarcoglycan, an important component of the muscle cell membrane. When this protein is deficient or absent, muscle fibers become more vulnerable to damage.
</div>
<div><br />
</div>
<div>Gene therapy represents a fundamentally different approach: instead of treating only the consequences of muscle degeneration, it aims to address the underlying genetic cause by delivering a functional copy of the affected gene to muscle cells.
</div>
<div><br />
</div>
<div>Modern gene-therapy research has demonstrated that this concept is not merely theoretical. Gene therapies for other rare genetic diseases have already produced remarkable scientific breakthroughs, showing that genetic medicine can transform diseases that were once considered extremely difficult or impossible to treat.
</div>
<div><br />
</div>
<div>For someone living with a progressive genetic disease, these advances are more than scientific headlines.
</div>
<div><br />
</div>
<div>They are hope.
</div>
<div><br />
</div>
<div>They represent the possibility of preserving what I still have before more of it is taken away.
</div>
<div><br />
</div>
<div><strong>Why $2.3 Million?</strong>
</div>
<div><br />
</div>
<div>A price of approximately $2.3 million for a gene therapy can sound impossible to understand at first.
</div>
<div><br />
</div>
<div>But the cost of developing a treatment for an ultra-rare disease is fundamentally different from developing a medication for a condition affecting millions of people.
</div>
<div><br />
</div>
<div>Gene therapies require highly specialized biological manufacturing, extensive research, rigorous quality control, clinical development, and complex delivery systems.
</div>
<div><br />
</div>
<div>One important platform is the use of adeno-associated virus (AAV) vectors. These engineered viral vectors can be used as delivery vehicles to transport therapeutic genetic material into target cells. Manufacturing AAV-based therapies at the required clinical quality and scale is technically complex and expensive.
</div>
<div><br />
</div>
<div>When a disease affects only a small number of people, the enormous costs of research, clinical trials, manufacturing, regulatory development, and long-term follow-up are distributed across a very small patient population.
</div>
<div><br />
</div>
<div>The price reflects the extraordinary complexity and rarity of this field—but behind that number is something much more important to me:
</div>
<div><br />
</div>
<div>the value of preserving a life that is still moving.
</div>
<div><br />
</div>
<div>I Am Not Asking for More Time. I Am Asking for a Chance.
</div>
<div>I cannot stop the clock.
</div>
<div><br />
</div>
<div>I cannot change the mutation that I was born with.
</div>
<div><br />
</div>
<div>And I cannot ask my muscles to wait patiently while science catches up.
</div>
<div><br />
</div>
<div>But I can ask for a chance.
</div>
<div><br />
</div>
<div>A chance to preserve my ability to walk.
</div>
<div><br />
</div>
<div>A chance to keep the independence that remains.
</div>
<div><br />
</div>
<div>A chance to wake up one morning without wondering whether yesterday was the last day I could do something as simple as walking across the room.
</div>
<div><br />
</div>
<div>Scientific progress has already shown what is possible. Gene therapy has moved from an idea in laboratories toward real treatments for serious genetic diseases. That progress gives patients like me something we desperately need: a reason to believe that the future does not have to be defined entirely by decline.
</div>
<div><br />
</div>
<div>My Greatest Fear—and My Greatest Hope
</div>
<div>My greatest fear is that I will lose the ability to walk before treatment becomes accessible to me.
</div>
<div><br />
</div>
<div>My greatest hope is that science moves quickly enough to change that story.
</div>
<div><br />
</div>
<div>I do not want people to see only a rare disease, a genetic mutation, or a price tag.
</div>
<div><br />
</div>
<div>I want them to see a person.
</div>
<div><br />
</div>
<div>Someone who remembers what it was like to move without thinking.
</div>
<div><br />
</div>
<div>Someone who still dreams, still hopes, still fights.
</div>
<div><br />
</div>
<div>Someone whose future should not be determined by how quickly a progressive disease can destroy muscle.
</div>
<div><br />
</div>
<div>Because for me, time is not just time anymore. Time is muscle. Time is movement. Time is independence. Time is life.
</div>
<div><br />
</div>
<div>And that is why every day matters.
</div>
<div><br />
</div>
<div>With Gratitude
</div>
<div>To every scientist, physician, researcher, patient advocate, family member, donor, and person who believes that rare diseases deserve attention and hope: thank you.
</div>
<div><br />
</div>
<div>Thank you for advancing science when the path is difficult.
</div>
<div><br />
</div>
<div>Thank you for refusing to accept that rarity should mean invisibility.
</div>
<div><br />
</div>
<div>And thank you for helping bring us closer to a future in which genetic diseases are not simply managed, but fundamentally changed.
</div>
<div><br />
</div>
<div>I am grateful for every person who chooses to stand beside patients like me.
</div>
<div><br />
</div>
<div>Because sometimes, hope is not about knowing exactly what tomorrow will bring.
</div>
<div><br />
</div>
<div>Sometimes, hope is simply having enough time for science to catch up.
</div>
<div><br />
</div>
<div><strong>Thank you for listening, for caring, and for believing that my future is worth fighting</strong>
</div>
<div>With love
</div>
<div>Anwar ❤️
</div>

Anonymous

KAHINA BENABDESLAM

Kahina Kabyle

Wednee Crowley

Hamdia Hyder

Help Anwar fight muscular dystrophy LGMD2D

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

be_supporter_comments_enabled_supported_funds

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help Anwar fight muscular dystrophy LGMD2D

Still $2,298,965 to go. Help us build momentum.